Mucosal Immunity and the Gut-Microbiota-Brain-Axis in Neuroimmune Disease.
Sterling, Kathryn G, Dodd, Griffin Kutler, Alhamdi, Shatha et al. · International journal of molecular sciences · 2022 · DOI
Quick Summary
This review article examines the connection between gut bacteria, immunity, and the brain in diseases like ME/CFS. The authors explain that the bacteria in our gut can communicate with our brain through chemical signals and nerves, but this communication can be disrupted in certain illnesses. They focus on how the immune system in the gut lining controls which bacteria thrive there, and how changes in these bacterial communities might contribute to neuroimmune diseases.
Why It Matters
Understanding how gut bacteria and mucosal immunity are altered in ME/CFS could reveal new therapeutic targets, as these systems directly influence neuroinflammation and symptom severity. This review consolidates evidence linking intestinal barrier dysfunction, immune dysregulation, and dysbiosis—three hallmarks often observed in ME/CFS—into a unified mechanistic framework that may guide future research and treatment development.
Observed Findings
Metagenomic studies show reduced microbial diversity in ME/CFS and other neuroimmune diseases compared to healthy controls
Mucosal IgA and tight junction integrity are altered in neuroimmune diseases and influence which bacterial species can colonize the gut
Gut bacteria produce small molecules (short-chain fatty acids, neurotransmitters) that enter circulation and reach the brain
The vagus nerve provides a direct anatomical pathway for bacterial metabolites and signals to influence central nervous system function
Mucosal immune dysregulation occurs alongside microbiota dysbiosis in ME/CFS, autism, Parkinson's disease, and Alzheimer's disease
Inferred Conclusions
Mucosal immune dysfunction may be a primary driver of dysbiosis in neuroimmune diseases, distinct from systemic immune changes
Altered gut barrier function and aberrant IgA responses reshape microbial communities in ways that amplify neuroinflammation
The gut-microbiota-brain axis represents a tractable target for therapeutic intervention in ME/CFS and related conditions
This review does not prove that dysbiosis causes ME/CFS or that restoring specific bacteria will cure the disease; most evidence is correlational rather than causally mechanistic. The review does not establish which mucosal immune changes are primary versus secondary consequences of ME/CFS pathology, nor does it provide patient-level data demonstrating clinical benefit from microbiota-targeted interventions.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Does mucosal immune dysfunction initiate dysbiosis in ME/CFS, or does dysbiosis trigger mucosal immune changes—or do both occur simultaneously?
Which specific bacterial taxa or metabolic pathways are most relevant to ME/CFS symptoms, and can restoring these taxa improve clinical outcomes?
How do individual variations in mucosal immunity explain heterogeneity in microbiota composition and symptom severity across ME/CFS patients?
Which mucosal immune-targeted interventions (probiotics, immunomodulation, barrier-enhancing agents) show promise in reducing dysbiosis and neuroinflammation in ME/CFS?